Literature DB >> 9828734

Randomised crossover trial of salbutamol aerosol delivered by metered dose inhaler, jet nebuliser, and ultrasonic nebuliser in chronic lung disease.

T F Fok1, K Lam, P C Ng, H K So, K L Cheung, W Wong, K W So.   

Abstract

AIMS: To compare the efficacy of salbutamol delivered by metered dose inhaler (MDI), jet nebuliser, and ultrasonic nebuliser in ventilated infants with chronic lung disease.
METHODS: Twenty preterm ventilated infants with chronic lung disease were enrolled in two studies. In study 1 (n = 10), each infant was given 200 micrograms of salbutamol at 4 hour intervals and in random sequence from a metered dose inhaler-spacer device, a jet nebuliser, and an ultrasonic nebuliser with a small medication cup. The infants were monitored for heart rate, transcutaneous pO2, pCO2, and oxygen saturation, respiratory system resistance and compliance before and after each treatment. Infants in study 2 (n = 10) were similarly studied except for the use of a different jet nebuliser.
RESULTS: The mean (SEM) maximum percentage decreases in respiratory system resistance, observed at 30 minutes after aerosol delivery were study 1: MDI: 44.3 (4.3)%; jet: 32.3 (3.4)%; ultrasonic: 56.1 (3.2)%; study 2: MDI: 28.6 (1.0)%; jet: 16.9 (1.4)%; ultrasonic: 42.1 (1.6)%. During the first hour after treatment, a significantly faster heart rate and higher transcutaneous pO2 were associated with the use of the ultrasonic nebuliser or MDI than with the jet nebulisers in both studies. The use of the ultrasonic nebuliser but not the other devices also resulted in a lower transcutaneous pCO2 and improved respiratory system compliance in study 2.
CONCLUSIONS: These findings suggest that among the devices tested, the delivery of salbutamol aerosol to the lower respiratory tract was greatest using the ultrasonic nebuliser, and least with the jet nebulisers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828734      PMCID: PMC1720846          DOI: 10.1136/fn.79.2.f100

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  23 in total

Review 1.  Aerosol therapy in the newborn.

Authors:  M Silverman
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

2.  Evaluation of nebulizers for use in neonatal ventilator circuits.

Authors:  D Cameron; M Clay; M Silverman
Journal:  Crit Care Med       Date:  1990-08       Impact factor: 7.598

3.  Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease.

Authors:  R A Wilkie; M H Bryan
Journal:  J Pediatr       Date:  1987-08       Impact factor: 4.406

4.  Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia.

Authors:  W H Northway; R C Rosan; D Y Porter
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

5.  Pulmonary deposition of salbutamol aerosol delivered by metered dose inhaler, jet nebulizer, and ultrasonic nebulizer in mechanically ventilated rabbits.

Authors:  T F Fok; M Al-Essa; S Monkman; M Dolovich; L Girard; G Coates; H Kirpalani
Journal:  Pediatr Res       Date:  1997-11       Impact factor: 3.756

6.  Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia.

Authors:  K L Brundage; K G Mohsini; A B Froese; J T Fisher
Journal:  Am Rev Respir Dis       Date:  1990-11

7.  Delivery of aerosolized medication to intubated babies.

Authors:  K L Watterberg; A R Clark; H W Kelly; S Murphy
Journal:  Pediatr Pulmonol       Date:  1991

8.  Aerosol delivery to the rabbit lung with an infant ventilator.

Authors:  M Flavin; M MacDonald; M Dolovich; G Coates; H O'Brodovich
Journal:  Pediatr Pulmonol       Date:  1986 Jan-Feb

9.  Early onset of airway reactivity in premature infants with bronchopulmonary dysplasia.

Authors:  E K Motoyama; M D Fort; K W Klesh; R L Mutich; R D Guthrie
Journal:  Am Rev Respir Dis       Date:  1987-07

10.  Increased compliance in response to salbutamol in premature infants with developing bronchopulmonary dysplasia.

Authors:  A Rotschild; A Solimano; M Puterman; J Smyth; A Sharma; S Albersheim
Journal:  J Pediatr       Date:  1989-12       Impact factor: 4.406

View more
  6 in total

Review 1.  Current perspectives on the prevention and management of chronic lung disease in preterm infants.

Authors:  Prakesh S Shah
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 2.  Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.

Authors:  Geraldine Ng; Orlando da Silva; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2016-12-14

Review 3.  Updates on Functional Characterization of Bronchopulmonary Dysplasia - The Contribution of Lung Function Testing.

Authors:  Anne Greenough; Anoop Pahuja
Journal:  Front Med (Lausanne)       Date:  2015-05-29

4.  Development of an ex vivo respiratory pediatric model of bronchopulmonary dysplasia for aerosol deposition studies.

Authors:  Yoann Montigaud; Sophie Périnel; Jean-Christophe Dubus; Lara Leclerc; Marie Suau; Clémence Goy; Anthony Clotagatide; Nathalie Prévôt; Jérémie Pourchez
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

5.  Response to first dose of inhaled albuterol in mechanically ventilated preterm infants.

Authors:  Thomas M Raffay; Mandy Brasher; Brooke C Place; Abhijit Patwardhan; Peter J Giannone; Henrietta Bada; Philip M Westgate; Elie G Abu Jawdeh
Journal:  J Perinatol       Date:  2021-05-25       Impact factor: 2.521

Review 6.  Systematic Review of Inhaled Bronchodilator and Corticosteroid Therapies in Infants with Bronchopulmonary Dysplasia: Implications and Future Directions.

Authors:  Brian J Clouse; Sudarshan R Jadcherla; Jonathan L Slaughter
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.